Chapter 7 Therapeutic Human Papillomavirus ( HPV ) Vaccines

Cervical cancer trends to occur in midlife. Most cases are found in women younger than 50. More than 15% of cases of cervical cancer are found in women over 65 but, these cancers rarely arrise in women who have regular tests for cervical cancer screening before they were 65. The most important etiological factor in cervical cancer and precursor lesions is persistent infection by HPV. Thus, an effective HPV vaccine program will be decreasing mortality and morbidity of diseases mediated HPV. FDA [Food and Dreug Administration of the United States] approved to two profilactic vaccines for prevention of HPV dissemination. These vaccines have no therapeutic efficacy on infections and lesions of HPV. Studies on therapeutic vaccines have been proceeding. Therapeutic vaccines purposes be developed cellular immunity against infected cells by stimulating the patients’ immune responses [1].